Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals

Background— Information about physicians’ adherence to cholesterol management guidelines remains scant. The present survey updates our knowledge of lipid management worldwide. Methods and Results— Lipid levels were determined at enrollment in dyslipidemic adult patients on stable lipid-lowering therapy in 9 countries. The primary end point was the success rate, defined as the proportion of patients achieving appropriate low-density lipoprotein cholesterol (LDL-C) goals for their given risk. The mean age of the 9955 evaluable patients was 62±12 years; 54% were male. Coronary disease and diabetes mellitus had been diagnosed in 30% and 31%, respectively, and 14% were current smokers. Current treatment consisted of a statin in 75%. The proportion of patients achieving LDL-C goals according to relevant national guidelines ranged from 47% to 84% across countries. In low-, moderate-, and high-risk groups, mean LDL-C was 119, 109, and 91 mg/dL and mean high-density lipoprotein cholesterol was 62, 49, and 50 mg/dL, respectively. The success rate for LDL-C goal achievement was 86% in low-, 74% in moderate-, and 67% in high-risk patients (73% overall). However, among coronary heart disease patients with ≥2 risk factors, only 30% attained the optional LDL-C goal of <70 mg/dL. In the entire cohort, high-density lipoprotein cholesterol was <40 mg/dL in 19%, 40 to 60 mg/dL in 55%, and >60 mg/dL in 26% of patients. Conclusions— Although there is room for improvement, particularly in very-high-risk patients, these results indicate that lipid-lowering therapy is being applied much more successfully than it was a decade ago.

[1]  A. Gotto,et al.  Improving lipid goal attainment: is it enough? , 2009, Circulation.

[2]  S. King,et al.  Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required , 2008, Circulation.

[3]  M. Sabatine,et al.  Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. , 2008, Journal of the American College of Cardiology.

[4]  Marc A Pfeffer,et al.  Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. , 2008, Journal of the American College of Cardiology.

[5]  J. Bernarding,et al.  Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. , 2007, European heart journal.

[6]  R. Karas,et al.  Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. , 2007, The American journal of cardiology.

[7]  R. Gangnon,et al.  Implications of Cardiac Risk and Low-Density Lipoprotein Cholesterol Distributions in the United States for the Diagnosis and Treatment of Dyslipidemia: Data From National Health and Nutrition Examination Survey 1999 to 2002 , 2007, Circulation.

[8]  Lawrence A Leiter,et al.  Contemporary management of dyslipidemia in high-risk patients: targets still not met. , 2006, The American journal of medicine.

[9]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[10]  A. González-Quintela,et al.  [Prevalence of cardiovascular risk factors in the Spanish working population]. , 2006, Revista espanola de cardiologia.

[11]  E. D. de Faria,et al.  The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Brazilian population. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[12]  M. A. Sánchez-Chaparro,et al.  Prevalencia de factores de riesgo vascular en la población laboral española , 2006 .

[13]  E. Bruckert,et al.  High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients , 2005, Current medical research and opinion.

[14]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[15]  J. Mckenney,et al.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. , 2005, The American journal of cardiology.

[16]  D. Arveiler,et al.  [Prevalence of dyslipidaemias in a representative sample of the French population]. , 2005, Archives des maladies du coeur et des vaisseaux.

[17]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[18]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[19]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[21]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[22]  S. Heymsfield,et al.  Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. , 2002, The American journal of clinical nutrition.

[23]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[24]  J. Little,et al.  Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. , 1999, The Canadian journal of cardiology.

[25]  David M. Herrington,et al.  Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) , 1997 .

[26]  Bittner,et al.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.

[27]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[28]  G. Dagenais,et al.  Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) , 1995, The American journal of cardiology.

[29]  G. Moneta Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals , 2010 .

[30]  Michael Miller Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[31]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[32]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[33]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .